Nk depletion antibody anti asialo gm1

Manufactured by Fujifilm

The NK depletion antibody (anti-asialo-GM1) is a laboratory reagent used for the selective depletion of natural killer (NK) cells. It binds to the asialo-GM1 antigen, which is expressed on the surface of NK cells, allowing for their identification and removal from a sample.

Automatically generated - may contain errors

Lab products found in correlation

αpd l1 10f 9g2, by BioXCell (2 mentions) Cd8 2.43, by BioXCell (2 mentions) Fty720, by Merck Group (1 mentions)

Spelling variants of this product

Anti-asialo GM1 (53 citations) Anti-asialo GM1 antibody (24 citations)

2 protocols using nk depletion antibody anti asialo gm1

Investigating Immunotherapeutic Agents

Check if the same lab product or an alternative is used in the 5 most similar protocols

N-803 was generously provided by NantBioScience under a Cooperative Research and Development Agreement with the National Cancer Institute. αPD-L1 (10F.9G2), CD8 (2.43), and CD4 (GK1.5) depletion antibodies were from BioXcell. The NK depletion antibody (anti-asialo-GM1) was from Wako Chemicals.

Knudson K.M., Hicks K.C., Alter S., Schlom J, & Gameiro S.R. (2019). Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. Journal for Immunotherapy of Cancer, 7, 82.

+ Open protocol

+ Expand

Murine N-809 and N-803 Immunotherapies

Check if the same lab product or an alternative is used in the 5 most similar protocols

Murine N-809 and N-803 (previously ALT-803) were generously provided by ImmunityBio under a Cooperative Research and Development Agreement with the National Cancer Institute. Murine N-809 consists of N-803, an IL-15 N72D/IL-15RαSushi superagonist complex containing the Fc-domain of murine IgG2a fused to two anti-PD-L1 ScFv domains. αPD-L1 (10F.9G2) and CD8 (2.43) antibodies were from BioXcell. The NK depletion antibody (anti-asialo-GM1) was from Wako Chemicals. FTY720 was from Sigma.

Knudson K.M., Hicks K.C., Ozawa Y., Schlom J, & Gameiro S.R. (2020). Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist. Journal for Immunotherapy of Cancer, 8(1), e000493.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!